NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
Recruiting
- Conditions
- Prostatic HyperplasiaCancer Of ProstateProstatic CancerProstate CancerProstatic Neoplams
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10000
- Registration Number
- NCT03354416
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Gut Microbiome and p-Inulin in CKD - TarGut CKD Study
Not Applicable
- Conditions
- Chronic Kidney Diseases
- Interventions
- Dietary Supplement: Oligofructose-enriched inulin (p-inulin)Other: No treatment
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2017-11-21
- Target Recruit Count
- 18
- Registration Number
- NCT03348592
- Locations
- 🇺🇸
The George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
Phase 2
Active, not recruiting
- Conditions
- Recurrent Endometrial Endometrioid AdenocarcinomaRecurrent Malignant Uterine Corpus NeoplasmRecurrent Ovarian CarcinomaRecurrent Ovarian Clear Cell AdenocarcinomaRecurrent Ovarian Endometrioid Adenocarcinoma
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT03348631
- Locations
- 🇺🇸
Desert West Surgery, Las Vegas, Nevada, United States
🇺🇸Benefis Sletten Cancer Institute, Great Falls, Montana, United States
🇺🇸Great Falls Clinic, Great Falls, Montana, United States
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
Phase 1
Terminated
- Conditions
- Cervical CarcinomaEndometrioid AdenocarcinomaMalignant Female Reproductive System NeoplasmRecurrent Cervical CarcinomaStage I Uterine Corpus Cancer AJCC v7Stage I Vaginal Cancer AJCC v6 and v7Stage IA Uterine Corpus Cancer AJCC v7Stage IB Cervical Cancer AJCC v6 and v7Stage IB Uterine Corpus Cancer AJCC v7Stage IB2 Cervical Cancer AJCC v6 and v7
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT03345784
- Locations
- 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer
Completed
- Conditions
- Bladder Cancer
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT03327883
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
Phase 1
Withdrawn
- Conditions
- Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB PositiveHER2/Neu NegativeStage IV Breast Cancer AJCC v6 and v7Stage IV Cutaneous Melanoma AJCC v6 and v7Metastatic Malignant Solid NeoplasmProgesterone Receptor NegativeStage III Breast Cancer AJCC v7Stage III Uveal Melanoma AJCC v7
- Interventions
- Biological: IpilimumabOther: Laboratory Biomarker AnalysisBiological: NivolumabOther: Pharmacological Study
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03326258
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
Phase 1
Completed
- Conditions
- Breast Ductal Carcinoma In SituBreast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaInvasive Breast CarcinomaBreast Lobular Carcinoma In Situ
- Interventions
- Other: Questionnaire Administration
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT03323658
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
Phase 1
Active, not recruiting
- Conditions
- Recurrent Transformed Non-Hodgkin LymphomaRefractory Transformed Non-Hodgkin LymphomaTransformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRichter SyndromeRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT03321643
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
Phase 1
Active, not recruiting
- Conditions
- Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingOther: Quality-of-Life AssessmentRadiation: Radium Ra 223 Dichloride
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 133
- Registration Number
- NCT03317392
- Locations
- 🇺🇸
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
Phase 1
Active, not recruiting
- Conditions
- Stage IA Breast Cancer AJCC v7Breast Lobular Carcinoma In SituStage III Breast Cancer AJCC v7Breast Ductal Carcinoma In SituStage 0 Breast Cancer AJCC v6 and v7Stage I Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage IIB Breast Cancer AJCC v6 and v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT03317405
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath